2219892
Project Grant
Overview
Grant Description
Sbir Phase I: Safety Syringe Needle for Prevention of Unintended/Accidental Puncture (Needlestick Injury) -The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a novel medical device for intramuscular injections that will reduce needlestick injury.
Unintended or accidental puncture is the second most common occupational hazard for healthcare staff. An estimated 385,000 needlestick injuries occur in the United States each year impacting 5.6 million healthcare workers. Needlestick injury represents one of the largest risks, both financially ($258 million annually) and medically (e.g., bloodborne pathogen exposure), to healthcare providers.
This project aims to develop a novel, flexible hypodermic needle with a safety syringe that enables rapid injections while replacing sharp needles and significantly reducing risks of unintended health care provider injury.
This Small Business Innovation Research Phase I project provides a novel, flexible, polymer needle-based safety syringe for health care providers to perform intramuscular injections in patients. A novel and variable stiffness shaft is integrated with an external safety lumen mechanism to create an integrated delivery system with the same delivery reliability and repeatability as standard needlesticks.
The design will be prototyped and evaluated under a variety of human factors considerations. The device will be required to pass several mechanical tests for puncture, insertion, and lumen integrity in a consistent manner, as anticipated during routine clinical use.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Unintended or accidental puncture is the second most common occupational hazard for healthcare staff. An estimated 385,000 needlestick injuries occur in the United States each year impacting 5.6 million healthcare workers. Needlestick injury represents one of the largest risks, both financially ($258 million annually) and medically (e.g., bloodborne pathogen exposure), to healthcare providers.
This project aims to develop a novel, flexible hypodermic needle with a safety syringe that enables rapid injections while replacing sharp needles and significantly reducing risks of unintended health care provider injury.
This Small Business Innovation Research Phase I project provides a novel, flexible, polymer needle-based safety syringe for health care providers to perform intramuscular injections in patients. A novel and variable stiffness shaft is integrated with an external safety lumen mechanism to create an integrated delivery system with the same delivery reliability and repeatability as standard needlesticks.
The design will be prototyped and evaluated under a variety of human factors considerations. The device will be required to pass several mechanical tests for puncture, insertion, and lumen integrity in a consistent manner, as anticipated during routine clinical use.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF22551
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Ipswich,
Massachusetts
01938-1063
United States
Geographic Scope
Single Zip Code
Related Opportunity
22-551
Analysis Notes
Amendment Since initial award the End Date has been extended from 01/31/24 to 01/31/25 and the total obligations have increased 8% from $249,369 to $269,369.
GNU Co was awarded
Project Grant 2219892
worth $269,369
from National Science Foundation in May 2023 with work to be completed primarily in Ipswich Massachusetts United States.
The grant
has a duration of 1 year 8 months and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I:Safety Syringe Needle for Prevention of Unintended/Accidental Puncture (Needlestick Injury)
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a novel medical device for intramuscular injections that will reduce needlestick injury. Unintended or accidental puncture is the second most common occupational hazard for healthcare staff. An estimated 385,000 needlestick injuries occur in the United States each year impacting 5.6 million healthcare workers. Needlestick injury represents one of the largest risks, both financially ($258 million annually) and medically (e.g., bloodborne pathogen exposure), to healthcare providers. This project aims to develop a novel, flexible hypodermic needle with a safety syringe that enables rapid injections while replacing sharp needles and significantly reducing risks of unintended health care provider injury._x000D_ _x000D_ This Small Business Innovation Research Phase I project provides a novel, flexible, polymer needle-based safety syringe for health care providers to perform intramuscular injections in patients. A novel and variable stiffness shaft is integrated with an external safety lumen mechanism to create an integrated delivery system with the same delivery reliability and repeatability as standard needlesticks. The design will be prototyped and evaluated under a variety of human factors considerations. The device will be required to pass several mechanical tests for puncture, insertion, and lumen integrity in a consistent manner, as anticipated during routine clinical use._x000D_ _x000D_ This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
MD
Solicitation Number
NSF 22-551
Status
(Complete)
Last Modified 11/20/24
Period of Performance
5/1/23
Start Date
1/31/25
End Date
Funding Split
$269.4K
Federal Obligation
$0.0
Non-Federal Obligation
$269.4K
Total Obligated
Activity Timeline
Transaction History
Modifications to 2219892
Additional Detail
Award ID FAIN
2219892
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
PUT8PGBLNR19
Awardee CAGE
90AP0
Performance District
MA-06
Senators
Edward Markey
Elizabeth Warren
Elizabeth Warren
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
Research and Related Activities, National Science Foundation (049-0100) | General science and basic research | Grants, subsidies, and contributions (41.0) | $249,369 | 100% |
Modified: 11/20/24